D.E. Shaw & Co
CERE

D.E. Shaw & Co’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

D.E. Shaw & Co’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-44,442
Closed -$1.82M – 5026
2024
Q2 		$1.82M Sell
44,442
-377,573
-89% -$15.7M ﹤0.01% 2730
2024
Q1 		$17.8M Buy
+422,015
New +$17.7M 0.02% 983
2022
Q1 		– Sell
-8,700
Closed -$282K – 6055
2021
Q4 		$282K Sell
8,700
-14,881
-63% -$525K ﹤0.01% 4709
2021
Q3 		$696K Buy
+23,581
New +$662K ﹤0.01% 3870

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

D.E. Shaw & Co's CERE Position: Q3 2024 in Review

D.E. Shaw & Co sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 44,442 shares — an estimated $1.82M sold.

D.E. Shaw & Co first reported a position in CERE in Q3 2021 and held it in 4 quarters. The position peaked at $17.8M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • D.E. Shaw & Co reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 44,442 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.82M.
  • D.E. Shaw & Co first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • D.E. Shaw & Co's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $17.8M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.